VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

PROSCA BLADDR 2021 | PROOF 302: adjuvant infigratinib in FGFR3-mutant invasive UC

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, outlines the rationale and background of the ongoing PROOF 302 study (NCT04197986), a randomized, double-blind, placebo-controlled, Phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations. Dr Grivas follows by highlighting recent data evaluating adjuvant treatment approaches in this patient population. This interview took place at the PROSCA/BLADDR 2021 congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter